CTNM

Contineum Therapeutics announced a proposed public offering of $75.0 million in December 2025. In March 2026, the company reported its fourth-quarter 2025 financial results and affirmed key clinical development milestones. Millennium Management LLC reported a 5.1% stake in April 2026. Contineum Therapeutics reported positive topline data from its Phase 1b trial of PIPE-791 for chronic pain in April 2026. The company reported its first-quarter 2026 financial results in May 2026. Daniel S. Lorrain, the Chief Scientific Officer, sold 4,170 shares of Class A Common Stock in May 2026. The company's stock increased by 212.68% from May 2, 2025, to April 30, 2026, and by 27.1% from the beginning of 2026 to May 8, 2026.